According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
Several other brokerages also recently commented on EGRX. Mizuho raised their price objective on shares of Eagle Pharmaceuticals from $47.00 to $65.00 and gave the stock a neutral rating in a research report on Tuesday, August 16th. TheStreet raised shares of Eagle Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, August 9th. Finally, Royal Bank Of Canada reaffirmed a buy rating and set a $78.00 price objective on shares of Eagle Pharmaceuticals in a research report on Monday, June 13th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $90.24.
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 66.75 on Tuesday. The firm’s 50-day moving average is $59.93 and its 200 day moving average is $47.88. Eagle Pharmaceuticals has a 52-week low of $33.02 and a 52-week high of $102.48. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 342.31 and a beta of 1.18.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.71 by $0.09. The company earned $40.90 million during the quarter, compared to the consensus estimate of $43.55 million. Eagle Pharmaceuticals had a net margin of 3.45% and a return on equity of 3.44%. The company’s quarterly revenue was up 581.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) EPS. On average, equities research analysts anticipate that Eagle Pharmaceuticals will post $3.21 earnings per share for the current year.
In other Eagle Pharmaceuticals news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of Eagle Pharmaceuticals stock in a transaction on Monday, August 15th. The shares were sold at an average price of $60.77, for a total transaction of $1,516,150.73. The transaction was disclosed in a filing with the SEC, which is available through this link. 18.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of EGRX. Royal Bank of Canada increased its position in Eagle Pharmaceuticals by 3.5% in the second quarter. Royal Bank of Canada now owns 12,351 shares of the specialty pharmaceutical company’s stock worth $479,000 after buying an additional 417 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Eagle Pharmaceuticals by 1.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 30,642 shares of the specialty pharmaceutical company’s stock worth $1,189,000 after buying an additional 510 shares in the last quarter. American Century Companies Inc. increased its position in Eagle Pharmaceuticals by 6.1% in the second quarter. American Century Companies Inc. now owns 114,901 shares of the specialty pharmaceutical company’s stock worth $4,457,000 after buying an additional 6,567 shares in the last quarter. Paulson & CO. Inc. purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $815,000. Finally, Panagora Asset Management Inc. increased its position in Eagle Pharmaceuticals by 4.0% in the second quarter. Panagora Asset Management Inc. now owns 79,540 shares of the specialty pharmaceutical company’s stock worth $3,085,000 after buying an additional 3,038 shares in the last quarter. 95.67% of the stock is currently owned by hedge funds and other institutional investors.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.